IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Comprehensive Review: Chronotherapeutic Drug Delivery System (CDDS)

[1] Ms.Bhagyashri Laxman Gore, [2] Ms.Pooja Muthyamraj Battul, [3 Ms].Pratiksha Siddheshwar Bagade

[4] Mr.Suhas Lalsing Chavan, [5] Ms.Dipali Vilas Chavan,

SVERI'S Collage of Pharmacy Pandharpur,

Punyashlok Ahilyadevi Holkar Solapur University

Abstract: Chronotherapeutic drug delivery systems (CDDS) are designed to synchronize drug release with the body's biological rhythms to optimize therapeutic outcomes. Numerous pathological conditions such as asthma, hypertension, rheumatoid arthritis, peptic ulcer disease, and cardiovascular disorders exhibit circadian variation in symptom severity. Conventional dosage forms fail to accommodate these temporal changes, often leading to suboptimal efficacy or increased adverse effects. CDDS aim to provide time-programmed, pulsatile, or site-specific drug release corresponding to disease rhythm. This review highlights the biological basis of chronotherapy, formulation strategies, advanced technologies, evaluation parameters, marketed products, and future research directions. The integration of chronobiology with modern pharmaceutical engineering offers promising opportunities for personalized medicine.

Index Terms **-** Chronotherapy, Circadian rhythm, Pulsatile drug delivery, Lag time, Time-controlled release, Chrono pharmaceutics.

I. INTRODUCTION

Biological systems follow rhythmic cycles that influence physiological and pathological processes. The central biological clock, located in the suprachiasmatic nucleus (SCN) of the hypothalamus, regulates circadian rhythms of approximately 24 hours. These rhythms influence hormone secretion, gastric pH, blood pressure, heart rate, and metabolic activity.

Several diseases demonstrate predictable daily patterns. For example, asthma symptoms intensify during early morning hours, blood pressure exhibits a morning surge, and rheumatoid arthritis symptoms are more severe upon awakening. Conventional immediate-release or sustained-release formulations provide constant plasma concentrations but do not address time-dependent fluctuations in disease severity. Chronotherapeutic drug delivery systems are therefore developed to align drug release with biological timing.

2. Chronobiological Basis of Drug Therapy

2.1 Circadian Rhythm and Physiology

Circadian rhythms regulate:

- Cortisol secretion (peak in early morning)
- Melatonin release (peak at night)
- Gastric acid production (higher at night)
- Platelet aggregation (higher in morning)

These variations significantly affect drug absorption, distribution, metabolism, and elimination.

2.2 Chronopharmacokinetics and Chronopharmacodynamics

Chronopharmacokinetics refers to time-dependent changes in drug plasma concentration, while chronopharmacodynamics relates to time-dependent variations in drug response. Hepatic enzyme activity, renal clearance, and receptor sensitivity vary across the day, influencing therapeutic outcomes.

3. Rationale for Chronotherapeutic Drug Delivery

The development of CDDS is supported by:

1. Time-dependent disease symptoms.
2. Variation in drug toxicity according to dosing time.
3. Improved therapeutic index.
4. Reduction in adverse drug reactions.
5. Enhancement of patient compliance.

For instance, bedtime administration of antihypertensive agents reduces early morning cardiovascular risk.

4. Design Principles of Chronotherapeutic Systems

An effective CDDS should:

- Provide a predetermined lag time.
- Prevent drug release during the lag phase.
- Deliver rapid and complete drug release after lag time.
- Maintain reproducible performance.
- Ensure stability under physiological conditions.

The lag time is typically programmed between 3–6 hours depending on disease requirement.

5. Approaches to Chronotherapeutic Drug Delivery

5.1 Time-Controlled Systems

These systems release drug after a specific lag period independent of environmental factors.
Examples include:

- Press-coated tablets
- Osmotic pump systems
- Rupturable coating systems

5.2 Pulsatile Drug Delivery Systems

Pulsatile systems release drug in rapid bursts following a defined lag phase. They may be:

- Single-unit systems (tablet/capsule)
- Multi-unit particulate systems (pellets/beads)
- Capsule-based systems with erodible plugs



5.3 Stimuli-Responsive Systems

Drug release is triggered by physiological stimuli such as:

- pH variation
- Enzymatic activity
- Temperature change
- Magnetic or electric field



6. Technologies in Chronotherapeutics

Advanced proprietary technologies include:

- OROS® osmotic pump systems
- CODAS® (Chronotherapeutic Oral Drug Absorption System)
- DIFFUCAPS® multiparticulate bead system
- TIMERx® hydrophilic matrix technology

These platforms enable delayed and pulsatile drug release for optimized therapy.

7. Therapeutic Applications

Chronotherapeutic systems are beneficial in:

Disease	Peak Symptom Time
Asthma	Early morning
Hypertension	Morning surge
Rheumatoid arthritis	Morning
Peptic ulcer	Night
Myocardial infarction	Early morning
ADHD	Daytime

8. Marketed Chronotherapeutic Products

Several commercially available products incorporate chronotherapeutic principles:

- **Verelan PM**
- **Covera-HS**
- **Innopran XL**
- **Uniphyl**

These products are primarily used in cardiovascular and respiratory disorders requiring time-specific drug release.

9. Evaluation of Chronotherapeutic Systems

9.1 In-Vitro Evaluation

- Dissolution testing with lag time measurement
- Swelling index determination
- Rupture strength testing
- Drug content uniformity

9.2 In-Vivo Evaluation

- Pharmacokinetic profiling
- Chronopharmacodynamic assessment
- Bioavailability comparison

9.3 Stability Studies

Conducted according to ICH guidelines to ensure formulation integrity.

10. Advantages and Limitations

Advantages

- Optimized therapeutic response
- Reduced side effects
- Improved patient compliance
- Targeted drug delivery

Limitations

- Complex formulation design
- Higher manufacturing cost
- Inter-individual circadian variability
- Limited suitability for some drugs

11. Future Perspectives

Future research directions include:

- Nanotechnology-based pulsatile carriers
- 3D-printed chrono modulated tablets
- Artificial intelligence-based circadian modeling
- Personalized chronotherapy using wearable health monitoring devices

The integration of chronobiology with precision medicine is expected to transform drug therapy in coming years.

12. Conclusion

Chronotherapeutic drug delivery systems represent a sophisticated and rational approach to disease management. By aligning drug release with circadian rhythms, these systems enhance efficacy while minimizing toxicity. Despite formulation challenges, advancements in polymer science and smart delivery technologies continue to expand the clinical potential of chronotherapy. CDDS is poised to play a vital role in the future of personalized pharmaceutical care.

References

1. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007;59(9–10):828–851.

2. Youan BB. Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery? J Control Release. 2004;98(3):337–353.

3. Lemmer B. Chronopharmacology: implications for drug treatment. J Pharm Pharmacol. 1999;51(8):887–890.

4. Maroni A, Zema L, Del Curto MD, Foppoli A, Gazzaniga A. Oral pulsatile drug delivery systems. Expert Opin Drug Deliv. 2005;2(5):855–871.

5. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: current perspectives. J Control Release. 2009;134(2):74–80.

6. Patel VR, Patel HV. Pulsatile drug delivery system: a review. Int J Pharm Investig. 2010;1(1):2–8.

7. Sajan J, Cinu TA, Chacko AJ, Litty J, Jaseeda T. Chronotherapeutics and chronotherapeutic drug delivery systems. Trop J Pharm Res. 2009;8(5):467–475.

8. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advances. 1st ed. New Delhi: Vallabh Prakashan; 2002.

9. Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics: A Treatise. 2nd ed. New Delhi: Vallabh Prakashan; 2012.

10. Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst. 2001;18(5):433–458.

11. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci. 2003;6(1):33–66.

12. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999;37(3):213–255.

13. Ohdo S. Chronotherapeutic strategy: rhythm monitoring, manipulation and disruption. Adv Drug Deliv Rev. 2010;62(9–10):859–875.

14. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Pulsatile drug delivery systems: an approach for controlled drug delivery. Indian J Pharm Sci. 2006;68(3):295–300.

15. Shidhaye SS, Lotlikar VM, Ghule AM, Phutane P. Pulsatile drug delivery system: a review. Int J Pharm Sci Nanotechnol. 2010;3(3):1200–1213.